EGFR and lung cancer: used second‐generation sequencing, Sanger sequencing, and quantitative PCR to detect mutations in common lung cancer driver genes such as EGFR and ALK in 24 PACC patients, and the results showed that all patients had no mutations in common driver genes [17].